arrow
I

Inês Pires da Silva

the university of sydney
H指数:36
被引数:5,477

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

黑色素瘤新辅助治疗的五年生存率:国际黑色素瘤新辅助治疗协作组(INMC)更新的汇总分析

2026-10-010
OAAI
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

III期黑色素瘤辅助治疗中的动态复发风险预测工具

2025-09-120
PRE
Evidence for alcohol-mediated hemolysis and erythrophagocytosis

酒精介导的溶血和吞噬红细胞的证据

2025-06-260
OA
Predictive performance of the clinicopathologic gene expression profile (CP-GEP) in identifying cutaneous melanoma patients for whom sentinel lymph node biopsy is unnecessary: A systematic review and meta-analysis

临床病理基因表达谱(CP-GEP)在识别无需行前哨淋巴结活检的皮肤黑色素瘤患者中的预测性能:一项系统评价和荟萃分析

2025-06-200
PREAI
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma

Fdg-pet与黑色素瘤新辅助免疫治疗的病理反应和生存率的关系

2025-03-250
OA
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance (vol 40, pg 88, 2022)

多组学分析:检查点抑制剂治疗的黑色素瘤:识别应答和耐药的预测因子,以及生物学不一致性的标志物(卷40,页88,2022)

2025-02-010
PRE
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma

晚期 Merkel Cell Carcinoma 患者接受抗 PD-(L)1 疗法后进展性疾病的治疗结果与管理

2025-02-010
PRE
Effectiveness of second-and-third line biologics in perianal Crohn's disease (pCD) - a multicenter propensity score-matched study
2025-01-220
PRE
Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy

头颈部皮肤黑色素瘤和其他部位黑色素瘤的临床病理特征和治疗结果的比较: 全身治疗的意义

2025-01-011
OAAI
Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
2024-07-010
OAAI
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases

单独Anti-PD-1或联合anti-CTLA-4治疗晚期黑色素瘤肝转移患者

2024-07-011
PRE